Muñoz Martín, A. J. http://orcid.org/0000-0001-6977-8249
,
Jiménez-Fonseca, P. http://orcid.org/0000-0003-4592-3813
Carmona-Bayonas, A. http://orcid.org/0000-0002-1930-9660
Martínez de Castro, E. http://orcid.org/0000-0002-5772-0741
Muñoz Langa, J. http://orcid.org/0000-0002-6942-8916
Pérez Segura, P. http://orcid.org/0000-0001-5049-7199
Rodríguez Lescure, A. http://orcid.org/0000-0002-6823-5290
Vera García, R. http://orcid.org/0000-0003-1524-3147
Article History
Received: 11 September 2019
Accepted: 8 December 2019
First Online: 23 December 2019
Compliance with ethical standards
:
: AJMM declares consulting or advisory role: Celgene, Sanofi, Pfizer, Bristol-Myers Squibb, LEO Pharma, Daiichi Sankyo, Bayer, Halozyme; speakers’ bureau: Rovi; research funding: Sanofi, LEO Pharma and patents, royalties, other intellectual property: risk assessment model in venous thromboembolism in patients with cancer. PJF has participated as speaker in meetings sponsored by Leo Pharma and Rovi, all without the scope of this project. ACB has participated as a speaker in meetings sponsored by Rovi and Leo Pharma, all without the scope of this project. EMC declares consulting or advisory role: Pfizer; speakers’ bureau: Celgene, Rovi, Leo Pharma, Roche, Sanofi, Shire. JML: no conflict of interest. PPS declares consulting or advisory role: Leo Pharma. ARL declares no conflict of interest. RVG declares consulting or advisory role: Roche Amgen, Merck and Sanofi.
: The study has been performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. This study is an observational, non-interventionist trial.
: Signed informed consent was obtained from all patients.